BlackRock’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $411M | Sell |
2,169,622
-62,567
| -3% | -$11.8M | 0.01% | 1354 |
|
|
2026
Q1 | $440M | Sell |
2,232,189
-824,330
| -27% | -$159M | 0.01% | 1208 |
|
|
2025
Q4 | $562M | Buy |
3,056,519
+154,342
| +5% | +$27.1M | 0.01% | 1015 |
|
|
2025
Q3 | $445M | Buy |
2,902,177
+158,415
| +6% | +$24M | 0.01% | 1170 |
|
|
2025
Q2 | $383M | Buy |
2,743,762
+48,227
| +2% | +$6.76M | 0.01% | 1217 |
|
|
2025
Q1 | $396M | Buy |
2,695,535
+216,507
| +9% | +$31.3M | 0.01% | 1184 |
|
|
2024
Q4 | $325M | Sell |
2,479,028
-596,356
| -19% | -$83.5M | 0.01% | 1373 |
|
|
2024
Q3 | $479M | Sell |
3,075,384
-434,328
| -12% | -$70.1M | 0.01% | 1102 |
|
|
2024
Q2 | $547M | Buy |
3,509,712
+145,477
| +4% | +$21.9M | 0.01% | 941 |
|
|
2024
Q1 | $456M | Buy |
3,364,235
+99,821
| +3% | +$13.2M | 0.01% | 1099 |
|
|
2023
Q4 | $440M | Buy |
3,264,414
+87,735
| +3% | +$11.4M | 0.01% | 1109 |
|
|
2023
Q3 | $430M | Buy |
3,176,679
+19,516
| +0.6% | +$2.67M | 0.01% | 1006 |
|
|
2023
Q2 | $452M | Sell |
3,157,163
-1,371,960
| -30% | -$202M | 0.01% | 997 |
|
|
2023
Q1 | $629M | Sell |
4,529,123
-1,523,707
| -25% | -$205M | 0.02% | 764 |
|
|
2022
Q4 | $821M | Buy |
6,052,830
+530,672
| +10% | +$66.5M | 0.03% | 589 |
|
|
2022
Q3 | $606M | Sell |
5,522,158
-446,991
| -7% | -$56.7M | 0.02% | 711 |
|
|
2022
Q2 | $789M | Buy |
5,969,149
+2,235,903
| +60% | +$293M | 0.03% | 599 |
|
|
2022
Q1 | $495M | Buy |
3,733,246
+671,969
| +22% | +$80.6M | 0.01% | 986 |
|
|
2021
Q4 | $357M | Sell |
3,061,277
-1,092,720
| -26% | -$129M | 0.01% | 1288 |
|
|
2021
Q3 | $499M | Buy |
4,153,997
+66,622
| +2% | +$7.76M | 0.01% | 988 |
|
|
2021
Q2 | $490M | Sell |
4,087,375
-2,817,603
| -41% | -$309M | 0.01% | 1023 |
|
|
2021
Q1 | $687M | Buy |
6,904,978
+873,662
| +14% | +$87.8M | 0.02% | 778 |
|
|
2020
Q4 | $603M | Buy |
6,031,316
+2,558,446
| +74% | +$271M | 0.02% | 773 |
|
|
2020
Q3 | $381M | Sell |
3,472,870
-216,885
| -6% | -$24.1M | 0.01% | 912 |
|
|
2020
Q2 | $390M | Buy |
3,689,755
+352,188
| +11% | +$36.4M | 0.02% | 863 |
|
|
2020
Q1 | $298M | Buy |
3,337,567
+1,105,759
| +50% | +$104M | 0.01% | 891 |
|
|
2019
Q4 | $223M | Buy |
2,231,808
+97,437
| +5% | +$9.17M | 0.01% | 1404 |
|
|
2019
Q3 | $190M | Sell |
2,134,371
-196,087
| -8% | -$17M | 0.01% | 1438 |
|
|
2019
Q2 | $192M | Sell |
2,330,458
-4,530
| -0.2% | -$355K | 0.01% | 1463 |
|
|
2019
Q1 | $189M | Sell |
2,334,988
-195,597
| -8% | -$15.4M | 0.01% | 1449 |
|
|
2018
Q4 | $192M | Sell |
2,530,585
-700,244
| -22% | -$54.7M | 0.01% | 1348 |
|
|
2018
Q3 | $256M | Sell |
3,230,829
-78,076
| -2% | -$5.91M | 0.01% | 1289 |
|
|
2018
Q2 | $232M | Sell |
3,308,905
-4,155
| -0.1% | -$299K | 0.01% | 1347 |
|
|
2018
Q1 | $232M | Buy |
3,313,060
+124,299
| +4% | +$8.61M | 0.01% | 1248 |
|
|
2017
Q4 | $221M | Sell |
3,188,761
-325,026
| -9% | -$21.9M | 0.01% | 1290 |
|
|
2017
Q3 | $238M | Buy |
3,513,787
+536,962
| +18% | +$33.9M | 0.01% | 1199 |
|
|
2017
Q2 | $203M | Sell |
2,976,825
-478,504
| -14% | -$31.2M | 0.01% | 1293 |
|
|
2017
Q1 | $215M | Buy |
3,455,329
+3,454,129
| +287,844% | +$201M | 0.01% | 1223 |
|
|
2016
Q4 | $66K | Sell |
1,200
-109,238
| -99% | -$6.2M | ﹤0.01% | 2795 |
|
|
2016
Q3 | $7.26M | Buy |
+110,438
| New | +$7.22M | 0.01% | 823 |
|
|
2016
Q1 | – | Sell |
-1,285
| Closed | -$87K | – | 3644 |
|
|
2015
Q4 | $87K | Sell |
1,285
-18,815
| -94% | -$1.23M | ﹤0.01% | 1816 |
|
|
2015
Q3 | $1.28M | Sell |
20,100
-19,798
| -50% | -$1.3M | ﹤0.01% | 1199 |
|
|
2015
Q2 | $2.54M | Sell |
39,898
-1,027
| -3% | -$70.3K | ﹤0.01% | 1043 |
|
|
2015
Q1 | $2.8M | Sell |
40,925
-351
| -0.9% | -$24.4K | ﹤0.01% | 994 |
|
|
2014
Q4 | $2.9M | Buy |
41,276
+34,236
| +486% | +$2.45M | ﹤0.01% | 965 |
|
|
2014
Q3 | $503K | Sell |
7,040
-322
| -4% | -$23.6K | ﹤0.01% | 1347 |
|
|
2014
Q2 | $547K | Buy |
+7,362
| New | +$532K | ﹤0.01% | 1316 |
|
Other funds holding AZN
EP
IA
BlackRock's AZN Position: Q2 2026 in Review
BlackRock reduced its AstraZeneca (AZN) stake by 2.8% in Q2 2026, selling an estimated $11.8M and leaving 2,169,622 shares worth $411M. The position accounts for 0.01% of the portfolio, ranked #1354.
BlackRock first reported a position in AZN in Q2 2014 and has held it in 47 quarters since. The position peaked at $821M in Q4 2022. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- BlackRock held 2,169,622 shares of AstraZeneca worth $411M as of Q2 2026.
- BlackRock sold 62,567 AstraZeneca shares in Q2 2026, an estimated $11.8M.
- AstraZeneca made up 0.01% of BlackRock's portfolio in Q2 2026, its #1354 holding.
- BlackRock first reported a position in AstraZeneca in Q2 2014 and has held it in 47 quarters since.
- BlackRock's AstraZeneca position peaked at $821M in Q4 2022.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.